Florida-based AzurRx BioPharma is bolstering the company’s gastrointestinal disease pipeline with the $229 million acquisition of First Wave Bio and its small molecule therapeutics for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.
If you are not happy with the results below please do another search
50 search results for:
AbbVie is partnering with biotechnology firm REGENXBIO to develop and commercialize a new drug that could treat a wide range of eye diseases, including wet age-related macular degeneration (wet AMD).
Independent agency Connelly Partners (CP) announced Sept. 13 the launch of Connelly Partners Health (CP Health), a new dedicated health practice as part of the agency’s integrated offering.
An outbreak of dengue fever is suspected of killing dozens of people in India’s northern state of Uttar Pradesh since the start of September, and authorities launched a campaign to destroy mosquito breeding grounds.
The U.S. Food and Drug Administration accepted for review a Biologics License Application (BLA) for the anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy.
Britain’s state-run National Health Service will on Sept. 13 begin the world’s biggest trial of Grail Inc.’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.
U.S. President Joe Biden will announce new steps to slow the spread of Covid-19 before the U.N. General Assembly meets, Surgeon General Dr. Vivek Murthy said Sept. 12.
Vaccine developer Novavax Inc. said on Sept. 10 at least 2 billion doses of the company’s Covid-19 vaccine would be available in 2022.
Researchers from the Karolinska Institute in Sweden and University Children’s Hospital, Ruhr-University-Bochum, Germany, studied the impact of Covid-19 infections on lung function.
Three U.S. studies suggest Covid-19 vaccines offer strong protection against hospitalization and death, even in the face of the highly transmissible Delta variant, but vaccine protection appears to be waning among older populations, especially among those 75 and older.